Response to the announcement of a new Major Conditions Strategy
Responding to today’s Government announcement of a new ‘Major Conditions Strategy’, Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, said:
25 Jan 2023
Media StatementBreast Cancer Now responds to December's NHSE Waiting Times Data
Responding to the latest NHSE Cancer Waiting Times Data, Melanie Sturtevant, Associate Director for Policy, Evidence and Influencing at Breast Cancer Now, said:
17 Jan 2023
Media StatementWe respond to the launch of the first UK proton beam therapy trial for breast cancer patients
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, has commented on the launch of the first UK proton beam therapy trial for breast cancer patients.
03 Jan 2023
Media StatementWe respond to new estimates that 57,215 people were living with secondary (metastatic) breast cancer in England in 2020 to 2021
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, has commented on the new estimates.
22 Dec 2022
Media StatementWe respond to NICE’s approval of trastuzumab deruxtecan (Enhertu) for use on the Cancer Drugs Fund
Chief Executive of Breast Cancer Now, Baroness Delyth Morgan, has commented on NICE'S decision to approve trastuzumab deruxtecan for use on the Cancer Drugs Fund.
20 Dec 2022
Media StatementWe respond to double SMC drug announcement - adjuvant abemaciclib and alpelisib with fulvestrant
Chief Executive of Breast Cancer Now, Baroness Delyth Morgan, has commented on the double announcement by the Scottish Medicines Consortium.
12 Dec 2022
Media StatementWe respond to research about a potential new treatment for advanced breast cancer patients
Dr Kotryna Temcinaite, our senior research communications manager, commented on research presented at the 2022 San Antonio Breast Cancer Symposium, which showed the benefits of the drug capivasertib alongside hormone therapy for patients with advanced breast cancer.
08 Dec 2022
Media StatementWe respond to research about radiotherapy and long-term breast cancer survival
Dr Kotryna Temcinaite, our Senior Research Communications Manager, has responded to research presented at the 13th European Breast Cancer Conference about radiotherapy and long-term survival.
18 Nov 2022
Media StatementWe respond to research about the benefits of exercise
Dr Kotryna Temcinaite, our Senior Research Communications Manager, has commented on research published in JAMA Open Network about the benefits of exercise for women recovering from breast cancer.
18 Nov 2022
Media StatementWe respond to research about women with benign breast disease being at higher risk of breast cancer in the long term
Dr Kotryna Temcinaite, our Senior Research Communications Manager, has commented on research presented at the 13th European Breast Cancer Conference. This research showed that women who have benign breast conditions, including cysts and fibroadenomas, have a higher risk of developing breast cancer in the long term.
17 Nov 2022
Media StatementWe respond to latest NHSE Cancer Wait Times data
Melanie Sturtevant, Associate Director for Policy, Evidence and Influencing at Breast Cancer Now, has commented on the latest NHS England Cancer Wait Times data.
11 Nov 2022
Media StatementWe respond to NICE’s devastating decision to provisionally reject the use of olaparib on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said NICE’s decision to provisionally reject the use of olaparib on the NHS was "devastating".
10 Nov 2022